Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120434 | 0.74 | PDE4B (0.74) | PDE4BPDE3A | |
| SCHEMBL4115851 | 0.73 | PDE4B (1.00) | PDE4BPDE3A | |
| SCHEMBL4122533 | 0.73 | PDE4B (1.00) | PDE4BPDE3A | |
| SCHEMBL4115287 | 0.72 | PDE4B (1.00) | PDE4BPDE3A | |
| SCHEMBL4113856 | 0.69 | PDE4B (0.63) | PDE4BPDE3A | |
| SCHEMBL4354714 | 0.69 | PDE4B (0.63) | PDE4BPDE3A | |
| SCHEMBL4114254 | 0.68 | PDE4B (0.76) | PDE4BPDE3A | |
| SCHEMBL3207433 | 0.68 | PDE4B (0.67) | PDE4BPDE3A | |
| SCHEMBL10896574 | 0.67 | CYP2C9 (0.66) | CYP1A2CYP3A4CYP2C9CYP2C19HIF1A | |
| SCHEMBL4114250 | 0.67 | PDE4B (1.00) | PDE4BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | PDE4B 18/4885PDE3A 1/4885CYP1A2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.